Update on the Management of Crohn’s Disease

  • Anna M. Buchner
  • Wojciech Blonski
  • Gary R. Lichtenstein
Article

Abstract

Crohn’s disease (CD) is a chronic inflammatory disorder characterized by focal, asymmetric, transmural inflammation of any part of the luminal gastrointestinal tract of uncertain etiology and an unpredictable course. The available treatment options include aminosalicylates, budesonide and systemic corticosteroids, antibiotics, immunomodulators,methotrexate and anti-TNF agents. This review discusses recent developments in the treatment of CD and provides a comprehensive update on management of patients with CD based on the data from randomized controlled trials. Pique

Key words

Crohn’s disease Mesalamine Corticosteroids Budesonide Azathioprine 6-mercaptopurine Anti-TNF antibodies Infliximab Adalimumab Certolizumab pegol Natalizumab 

References

Papers of particular interest, published recently, have been highlighted as: •• Of outstanding importance

  1. 1.
    Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17.PubMedCrossRefGoogle Scholar
  2. 2.
    Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30:699–706.PubMedCrossRefGoogle Scholar
  3. 3.
    Schwartz DA, Loftus Jr EV, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Clemett D, Markham A. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn’s disease. Drugs. 2000;59:929–56.PubMedCrossRefGoogle Scholar
  5. 5.
    Haagen Nielsen O, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol. 1983;16:738–40.PubMedGoogle Scholar
  6. 6.
    Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study [ECCDS]: results of drug treatment. Gastroenterology. 1984;86:249–66.PubMedGoogle Scholar
  7. 7.
    Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group. Gastroenterology. 1993;104:1293–301.PubMedGoogle Scholar
  8. 8.
    Tremaine WJ, Schroeder KW, Harrison JM, et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine [5-ASA] preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastroenterol. 1994;19:278–82.PubMedCrossRefGoogle Scholar
  9. 9.
    Arber N, Odes HS, Fireman Z, et al. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn’s disease in remission. J Clin Gastroenterol. 1995;20:203–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Mahmud N, Kamm MA, Dupas JL, et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn’s colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut. 2001;49:552–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Gendre JP, Mary JY, Florent C, et al. Oral mesalamine [Pentasa] as maintenance treatment in Crohn’s disease: a multicenter placebo-controlled study. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives [GETAID]. Gastroenterology. 1993;104:435–9.PubMedGoogle Scholar
  12. 12.
    Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid [Asacol] in the maintenance treatment of Crohn’s disease. The Italian IBD Study Group. Gastroenterology. 1992;103:363–8.PubMedGoogle Scholar
  13. 13.
    Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study Group. Gastroenterology. 1997;112:1069–77.PubMedCrossRefGoogle Scholar
  14. 14.
    Thomson AB, Wright JP, Vatn M, et al. Mesalazine [Mesasal/Claversal] 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn’s disease. Aliment Pharmacol Ther. 1995;9:673–83.PubMedCrossRefGoogle Scholar
  15. 15.
    Brignola C, Iannone P, Pasquali S, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn’s disease. Dig Dis Sci. 1992;37:29–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Bresci G, Parisi G, Banti S. Long-term therapy with 5-aminosalicylic acid in Crohn’s disease: is it useful? Our four years experience. Int J Clin Pharmacol Res. 1994;14:133–8.PubMedGoogle Scholar
  17. 17.
    de Franchis R, Omodei P, Ranzi T, et al. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn’s disease. Aliment Pharmacol Ther. 1997;11:845–52.PubMedCrossRefGoogle Scholar
  18. 18.
    Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465–73.PubMedCrossRefGoogle Scholar
  19. 19.
    Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2010;12:CD008870.PubMedGoogle Scholar
  20. 20.
    •• Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-Aminosalicylates in Crohn’s Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2011. This is the most recent and up-to-date meta-analysis of the efficacy of sulfasalazine and newer mesalamine formulations in inducing and maintaining remission in patients with Crohn’s disease. It indicates that mesalamine formulations are not superior to placebo in treatment of Crohn’s disease.Google Scholar
  21. 21.
    •• Gordon M, Naidoo K, Thomas AG, et al.: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2011;1:CD008414. This is the most recent and up-to-date meta-analysis of the efficacy of sulfasalazine and newer mesalamine formulations in maintaining surgically induced remission in patients with Crohn’s disease. This study suggests that mesalamine formulations might be superior to placebo in these patients.PubMedGoogle Scholar
  22. 22.
    Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis. 2010;4:28–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–83. quiz 464, 484. Very comprehensive, up-to-date and evidence based description of the management of Crohn’s disease.PubMedCrossRefGoogle Scholar
  24. 24.
    Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;CD000296.Google Scholar
  25. 25.
    Sandborn WJ, Lofberg R, Feagan BG, et al. Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005;100:1780–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Benchimol EI, Seow CH, Otley AR, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;CD002913.Google Scholar
  27. 27.
    Rutgeerts P. The use of budesonide in the treatment of active Crohn’s disease is good clinical practice. Inflamm Bowel Dis. 2001;7:60–1. discussion 62–3.PubMedCrossRefGoogle Scholar
  28. 28.
    Faubion Jr WA, Loftus Jr EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Summers RW, Switz DM, Sessions Jr JT, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77:847–69.PubMedGoogle Scholar
  30. 30.
    Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut. 1997;41:209–14.PubMedCrossRefGoogle Scholar
  32. 32.
    Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2011.Google Scholar
  33. 33.
    Linskens RK, Huijsdens XW, Savelkoul PH, et al. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl. 2001;29–40.Google Scholar
  34. 34.
    Bamias G, Marini M, Moskaluk CA, et al. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn’s disease. J Immunol. 2002;169:5308–14.PubMedGoogle Scholar
  35. 35.
    Friswell M, Campbell B, Rhodes J. The role of bacteria in the pathogenesis of inflammatory bowel disease. Gut Liver. 2010;4:295–306.PubMedCrossRefGoogle Scholar
  36. 36.
    Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224–31.PubMedGoogle Scholar
  37. 37.
    Rahimi R, Nikfar S, Rezaie A, et al. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease. Clin Ther. 2006;28:1983–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108:1617–21.PubMedCrossRefGoogle Scholar
  39. 39.
    Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128:856–61.PubMedCrossRefGoogle Scholar
  40. 40.
    Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011.Google Scholar
  41. 41.
    Borgaonkar M, MacIntosh D, Fardy J, et al. Anti-tuberculous therapy for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;CD000299.Google Scholar
  42. 42.
    Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;CD000067.Google Scholar
  43. 43.
    Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2009;104:2089–96.PubMedCrossRefGoogle Scholar
  44. 44.
    •• Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2011. The most recent meta-analysis of the efficacy of azathioprine or 6-mercaptopurine in patients with Crohn’s disease. This analysis suggests that these agents are not superior to placebo in the treatment of patients with active or inactive Crohn’s disease.Google Scholar
  45. 45.
    Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;CD000067.Google Scholar
  46. 46.
    Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001;49:656–64.PubMedCrossRefGoogle Scholar
  48. 48.
    Peppercom MA. 6-mercaptopurine for the management of ulcerative colitis: a concept whose time has come. Am J Gastroenterol. 1996;91:1689–90.PubMedGoogle Scholar
  49. 49.
    Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343:1249–52.PubMedCrossRefGoogle Scholar
  50. 50.
    Kotlyar D, Blonski W, Porter D, et al. Hepatosplenic T-cell lymphoma [HSTCL] and inflammatory bowel disease [IBD]: a rare complication after long-term thiopurine exposure: case report and systematic review of the literature. Gastroenterology. 2009;136:A196.CrossRefGoogle Scholar
  51. 51.
    Navarro JT, Ribera JM, Mate JL, et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn’s disease treated with azathioprine. Leuk Lymphoma. 2003;44:531–3.PubMedCrossRefGoogle Scholar
  52. 52.
    Rosh JR, Oliva-Hemker M. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned. J Pediatr Gastroenterol Nutr. 2007;44:165–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265–7.PubMedCrossRefGoogle Scholar
  55. 55.
    •• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36–41.e1. Recent systematic review discussing factors contributing to the development of hepatospelnic T-cell lymphoma in patients treated with azathioprine and/or infliximab.PubMedCrossRefGoogle Scholar
  56. 56.
    Kotlyar DS, Gisbert JP, Lewis JD, et al. Overall incidence of hepatosplenic T cell lymphoma in patients with inflammatory bowel disease on thiopurines: a meta-analysis of three population based studies. Abstract accepted for Digestive Disease Week. Chicago, IL. May 7-May 10, 2011. 2011.Google Scholar
  57. 57.
    Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651–62.PubMedGoogle Scholar
  58. 58.
    Reuther LO, Sonne J, Larsen N, et al. Thiopurine methyltransferase genotype distribution in patients with Crohn’s disease. Aliment Pharmacol Ther. 2003;17:65–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000;118:1018–24.PubMedCrossRefGoogle Scholar
  60. 60.
    Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2005;CD003459.Google Scholar
  61. 61.
    Patel V, Macdonald JK, McDonald JW, et al. Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;CD006884.Google Scholar
  62. 62.
    Buckley LM, Vacek PM, Cooper SM. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1990;17:1158–61.PubMedGoogle Scholar
  63. 63.
    Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin [folinic acid] in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1993;36:795–803.PubMedCrossRefGoogle Scholar
  64. 64.
    Kremer JM, Alarcon GS, Lightfoot Jr RW, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;37:316–28.PubMedCrossRefGoogle Scholar
  65. 65.
    Remicade [Infliximab]. Prescribing information. Centocor Ortho Biotech Inc.Malvern, PA. 2009.Google Scholar
  66. 66.
    Humira [Adalimumab]. Prescribing Information. Abbott Laboratories, North Chicago, IL. 2010.Google Scholar
  67. 67.
    Cimzia [Certolizumab pegol]. Prescribing information. UCB Inc, Smyrna, GA. 2009.Google Scholar
  68. 68.
    Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644–53. A very important meta-analysis demonstrating the efficacy of anti-TNF antibodies in patients with Crohn’s disease.PubMedCrossRefGoogle Scholar
  69. 69.
    Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;CD006893.Google Scholar
  70. 70.
    •• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95. Data from recent SONIC trial suggesting that combination therapy with azathioprine and infliximab is the most efficacious regimen in patients with moderate to severe Crohn’s disease.PubMedCrossRefGoogle Scholar
  71. 71.
    Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol. 2003;98:2372–82.PubMedCrossRefGoogle Scholar
  72. 72.
    Natalizumab [Tysabri]. Prescribing information. Biogen Idec Inc., Cambridge, MA. 2010.Google Scholar
  73. 73.
    Honey K. The comeback kid: TYSABRI now FDA approved for Crohn disease. J Clin Invest. 2008;118:825–6.PubMedCrossRefGoogle Scholar
  74. 74.
  75. 75.
    MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;CD006097.Google Scholar
  76. 76.
    Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912–25.PubMedCrossRefGoogle Scholar
  77. 77.
    Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med. 2005;353:432–3.PubMedCrossRefGoogle Scholar
  78. 78.
    Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab–unforeseen consequences. N Engl J Med. 2005;353:414–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Lichtenstein GR, Hanauer SB, Kane SV, et al. Crohn’s is not a 6-week disease: lifelong management of mild to moderate Crohn’s disease. Inflamm Bowel Dis. 2004;10 Suppl 2:S2–10.PubMedGoogle Scholar
  80. 80.
    •• D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660–7. An important pilot study suggesting that “top down” therapeutic approach [infliximab and azathioprine combined] introduced at the early stage of Crohn’s disease is associated with better outcomes that “step up” [traditional] therapeutic approach.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Anna M. Buchner
    • 1
  • Wojciech Blonski
    • 1
    • 2
  • Gary R. Lichtenstein
    • 1
    • 3
  1. 1.Division of GastroenterologyUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of GastroenterologyMedical UniversityWroclawPoland
  3. 3.Gastroenterology DivisionUniversity of Pennsylvania School of Medicine, Hospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations